
CLAIMS

1. A compound having the general formula (XI)



(XI),


and pharmaceutically acceptable salts, hydrates and rotamers thereof;

wherein

C^1 is selected from the group consisting of aryl and heteroaryl, wherein the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S; and wherein said aryl and heteroaryl groups are optionally substituted with from 1 to 3 R^1 substituents;

C^2 is selected from the group consisting of aryl and heteroaryl, wherein the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S; and wherein said aryl and heteroaryl groups are optionally substituted with from 1 to 3 R^2 substituents;

C^3 is



,

wherein p is an integer selected from 0, 1, 2, or 3;

each R^1 is independently selected from the group consisting of halogen, —CN, -R^c, —CO_2R^a, —$CONR^aR^b$, —$C(O)R^a$, —$OC(O)NR^aR^b$, —$NR^bC(O)R^a$, —$NR^bC(O)_2R^c$, —NR^a—$C(O)NR^aR^b$, —$NR^aC(O)NR^aR^b$, —NR^aR^b, —OR^a, and —$S(O)_2NR^aR^b$; wherein each R^a and R^b is independently selected from hydrogen, $C_{1\text{-}8}$ alkyl, and $C_{1\text{-}8}$ haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, and is optionally substituted with one or two oxo; each R^c is independently selected from the group consisting of $C_{1\text{-}8}$ alkyl or heteroalkyl, $C_{1\text{-}8}$ haloalkyl, $C_{3\text{-}6}$ cycloalkyl, heterocycloalkyl, aryl and heteroaryl, and wherein the aliphatic and/or cyclic portions of R^a, R^b and R^c are optionally further substituted with from one to three halogen, hydroxy, methyl, amino, alkylamino and dialkylamino

groups; and optionally when two R^1 substituents are on adjacent atoms, are combined to form a fused five or six-membered carbocyclic or heterocyclic ring;

each R^2 is independently selected from the group consisting of halogen, —CN, —NO_2, —R^f, —CO_2R^d, —$CONR^dR^e$, —$C(O)R^d$, —$OC(O)NR^dR^e$, —$NR^eC(O)R^d$, —$NR^eC(O)_2R^f$, —$NR^dC(O)NR^dR^e$, —NR^dR^e, —OR^d, and —$S(O)_2NR^dR^e$; wherein each R^d and R^e is independently selected from hydrogen, C_{1-8} alkyl, and C_{1-8} haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, and is optionally substituted with one or two oxo; each R^f is independently selected from the group consisting of C_{1-8} alkyl or heteroalkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, heterocycloalkyl, aryl and heteroaryl, and wherein the aliphatic and/or cyclic portions of R^d, R^e and R^f are optionally further substituted with from one to three halogen, hydroxy, methyl, amino, alkylamino and dialkylamino groups, and optionally when two R^2 groups are on adjacent atoms, they are combined to form a five- or six-membered ring;

each R^3 is independently selected from the group consisting of halogen, —CN, —R^i, —CO_2R^g, —$CONR^gR^h$, —$C(O)R^g$, —$C(O)R^i$, —$OC(O)NR^gR^h$, —$NR^hC(O)R^g$, —$NR^hCO_2R^i$, —$NR^gC(O)NR^gR^h$, —NR^gR^h, —OR^g, —OR^j, —$S(O)_2NR^gR^h$, —X^4—R^j, —NH—X^4—R^j, —O—X^4—R^j, —X^4—NR^gR^h, —X^4—NHR^j, —X^4—$CONR^gR^h$, —X^4—$NR^hC(O)R^g$, —X^4—CO_2R^g, —O—X^4—CO_2R^g, —NH—X^4—CO_2R^g, —X^4—$NR^hCO_2R^i$, —O—X^4—$NR^hCO_2R^i$, —NHR^j and —$NHCH_2R^j$, wherein X^4 is a C_{1-4} alkylene; each R^g and R^h is independently selected from hydrogen, C_{1-8} alkyl or heteroalkyl, C_{3-6} cycloalkyl and C_{1-8} haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a four-, five- or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S and is optionally substituted with one or two oxo; each R^i is independently selected from the group consisting of C_{1-8} alkyl or heteroalkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and each R^j is selected from the group consisting of C_{3-6} cycloalkyl, imidazolyl, pyrimidinyl, pyrrolinyl, pyrrolyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and S,S-dioxo-tetrahydrothiopyranyl, and wherein the aliphatic and/or cyclic portions of R^g, R^h, R^i and R^j are optionally further substituted with from one to three halogen, methyl, CF_3, hydroxy, C_{1-4} alkoxy, C_{1-4} alkoxy-C_{1-4} alkyl, —C(O)O—C_{1-8} alkyl, amino, alkylamino and dialkylamino groups,


and optionally when two R^3 groups are on adjacent atoms, they are combined to form a five- or six-membered ring;

X is hydrogen or CH_3; and

R^8 is selected from the group consisting of chloro, C_1-C_4 alkyl, C_1-C_4 haloalkyl, and C_1-C_4 alkoxy, and wherein in the compound, one hydrogen may be replaced by deuterium.


2. The compound according to claim 1, wherein X is hydrogen.

3. The compound according to claim 1 or 2, wherein the compound has formula (XIa):



(XIa).

4. The compound according to any one of claims 1 to 3, wherein C^1 is




,

wherein

n is an integer selected from 0, 1, 2, or 3.

5. The compound according to any one of claims 1 to 4, wherein C^2 is




,

wherein


o is an integer selected from 0, 1, 2, or 3.

6. The compound according to any one of claims 1 to 5, wherein R_8 is selected from the group consisting of methyl, trifluoromethyl, and methoxy.


7. The compound according to any one of claims 1 to 6, wherein the compound is selected from the group consisting of




INF052,




INF053,




INF056,




INF067,




INF068,




INF069,




INF070,




INF071,




INF072,



INF075,



INF077, and



INF080.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 to 7.

9. The compound according to any one of claims 1 to 7 for use in medicine.

10. The compound according to any one of claims 1 to 7 for use in the treatment of a disease or disorder involving pathologic activation of a C5a receptor.

11. The compound for use according to claim 10, wherein the disease or disorder is selected from the group consisting of

- autoimmune disorders,
- inflammatory disorders or related conditions,
- cardiovascular or cerebrovascular disorders,
- HIV infection or AIDS,
- neurodegenerative disorders or related diseases, and

cancers or precancerous conditions.

12. Use of a compound according to any one of claims 1 to 7 in the preparation of a medicament for the treatment of a disease or disorder involving pathologic activation of a C5a receptor.

13. The use according to claim 12, wherein the disease or disorder is selected from the group consisting of

- autoimmune disorders,
- inflammatory disorders or related conditions,
- cardiovascular or cerebrovascular disorders,
- HIV infection or AIDS,
- neurodegenerative disorders or related diseases, and
- cancers or precancerous conditions.